Tactiva Therapeutics Secures $35 Million Series A Financing to Pursue Clinical Development of DEACT Platform Abstract Buffalo, NY, December 3, 2018 - Tactiva Therapeutics, development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, announced today it has secured a $35 million Series ... Read More
